Scarica l'app Stockscreener
5.15
0.39%
-0.02
Dopo l'orario di chiusura:
5.18
0.03
+0.58%
Chimerix Inc Borsa (CMRX) Ultime notizie
Chimerix gains on FDA review for brain tumor drug - MSN
Vontobel Holding Ltd. Sells 30,000 Shares of Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Chimerix Inc (CMRX)’S 1.77% Increase Makes It Worth Considering Again - Stocks Register
Wedbush Has Positive Outlook for Chimerix FY2025 Earnings - Defense World
Chimerix’s (CMRX) “Buy” Rating Reaffirmed at HC Wainwright - Armenian Reporter
Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients (CMRX) - Seeking Alpha
Financial Metrics Unveiled: Chimerix Inc (CMRX)’s Key Ratios in the Spotlight - The Dwinnex
Here's Why Momentum in Chimerix (CMRX) Should Keep going - Nasdaq
What is Wedbush’s Estimate for Chimerix FY2028 Earnings? - Defense World
Evaluating CMRX’s financial ratios for a profitable investment - US Post News
Chimerix stock soars to 52-week high, hits $5.17 - Investing.com India
Chimerix stock soars to 52-week high, hits $5.17 By Investing.com - Investing.com Nigeria
Chimerix Delivers More Than 130% Gain In Less Than 3 Months - RTTNews
Chimerix (NASDAQ:CMRX) Receives Buy Rating from HC Wainwright - Defense World
FDA accepts Chimerix's new drug application for glioma treatment By Investing.com - Investing.com Nigeria
Chimerix’s (CMRX) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Chimerix VP of finance sells $1,359 in stock - MSN
Sector Update: Health Care Stocks Mixed Late Afternoon -February 18, 2025 at 04:06 pm EST - Marketscreener.com
Chimerix Says FDA Grants Priority Review for New Drug Application of Cancer Treatment Dordaviprone; Shares Rise - Marketscreener.com
Chimerix stock gains on FDA review for lead drug (CMRX:NASDAQ) - Seeking Alpha
Wedbush Adjusts Price Target on Chimerix to $7 From $6, Keeps Outperform Rating - Marketscreener.com
Chimerix stock rises on FDA priority review for dordaviprone - Investing.com
Chimerix stock rises on FDA priority review for dordaviprone By Investing.com - Investing.com Nigeria
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma - Marketscreener.com
FDA accepts Chimerix's new drug application for glioma treatment - Investing.com India
Chimerix Announces FDA Acceptance And Priority Review Of New Drug Application For Dordaviprone - Marketscreener.com
Chimerix CFO sells $10,195 in stock amid tax obligation - MSN
Chimerix CEO Michael Andriole sells $33,282 in stock - MSN
Chimerix, Inc. (NASDAQ:CMRX) Insider Sells $13,792.50 in Stock - MarketBeat
Chimerix SVP and general counsel sells $7,226 in stock - MSN
Chimerix VP of finance sells $1,359 in stock By Investing.com - Investing.com Australia
Chimerix CFO sells $10,195 in stock amid tax obligation By Investing.com - Investing.com South Africa
Chimerix CEO Michael Andriole sells $33,282 in stock By Investing.com - Investing.com Nigeria
Chimerix SVP and general counsel sells $7,226 in stock By Investing.com - Investing.com South Africa
Chimerix chief medical officer Melemed sells $13,798 in stock - MSN
Chimerix chief medical officer Melemed sells $13,798 in stock By Investing.com - Investing.com Australia
Chimerix Executives Sell Shares to Cover Tax Liabilities - TradingView
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat
Peapod Lane Capital LLC Buys Shares of 754,566 Chimerix, Inc. (NASDAQ:CMRX) - MarketBeat
Chimerix stock soars to 52-week high, hits $4.3 - MSN
Chimerix stock soars to 52-week high, hits $4.3 By Investing.com - Investing.com Canada
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):